Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven L Highfill

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Human Gene Therapy|September 12, 2022
Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1Richard H Smith, Hanan Bloomer, Danielle Fink, et al.
Blood Advances|December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemiaAlexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 29, 2023
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domainLekha Mikkilineni, Danielle A Natrakul, Norris Lam, et al.
Blood Advances|December 7, 2020
NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous diseaseSuk See De Ravin, Julie Brault, Ronald J Meis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2022
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Human Gene Therapy|September 12, 2022
Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1Richard H Smith, Hanan Bloomer, Danielle Fink, et al.
Blood Advances|December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemiaAlexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 29, 2023
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domainLekha Mikkilineni, Danielle A Natrakul, Norris Lam, et al.
Blood Advances|December 7, 2020
NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous diseaseSuk See De Ravin, Julie Brault, Ronald J Meis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2022
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Pageof 6